Articles related to CANCER SCREENING

Research projects a 30% increase in early-onset cancers by 2030, highlighting the urgent need for adjusted screening protocols and preventive strategies in younger populations.

Early detection remains paramount – 90% of early-stage colon cancer patients survive at least 5 years after diagnosis, emphasizing the critical importance of timely screening.

In the BLUE-C trial, Cologuard Plus demonstrated a 93.9% sensitivity for colorectal cancer detection, significantly outperforming the 67.3% sensitivity of FIT.

AI-assisted diagnosis of lung cancer showed 87% sensitivity and 87% specificity in a meta-analysis, suggesting potential for improved accuracy in interpreting chest CT scans.

The FDA’s new mandate requires all mammography facilities to inform women about their breast density, recognizing its significance in cancer risk and detection challenges.

Medical errors are now recognized as the third leading cause of death in the US, emphasizing the urgent need for improved safety measures in healthcare settings.